Latest Aprea Therapeutics News & Updates

See the latest news and media coverage for Aprea Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Aprea Therapeutics

Biopharmaceutical company developing targeted cancer therapeutics

aprea.com

Headquarters: Doylestown, United States
Company type: Public company
Number of employees: 2–20
Industry: Pharmaceuticals

Last updated Today

Latest news about Aprea Therapeutics

In short: Aprea Therapeutics advanced APR-1051, its WEE1 inhibitor, with Phase 1 partial responses and accelerated enrollment ahead of Q4 2026 data.

Company announcements

September 22 Aprea Therapeutics

Aprea Therapeutics presents Phase 1 trial data

CEO Oren Gilad shares updates on the ACESOT-1051 trial at the EORTC-NCI-AACR Symposium with the oncology community.

June 1 Aprea Therapeutics

Aprea Therapeutics reports updated phase one WEE1 inhibitor data

Patients show partial responses and stable disease with manageable side effects, while dose expansion aims to finish by the second quarter of 2027.

May 13 Aprea Therapeutics

Aprea Therapeutics reports Q1 2026 financial results and updates

The company raised $30 million via private placement, holds $46.5 million in cash, highlighted early efficacy data for APR-1051, and appointed a new chief medical advisor.

March 30 Aprea Therapeutics

Aprea Therapeutics confirms partial response to its WEE1 inhibitor program

The Phase 1 ACESOT-1051 trial shows sustained tumor reduction in biomarker-defined cancers with manageable side effects and ongoing dose escalation plans.

Media coverage

September 10 Investing.com

Aprea Therapeutics at H.C. Wainwright conference: initial data improve outlooks By Investing.com

Aprea Therapeutics at H.C. Wainwright conference: initial data improve outlooks...

August 27 GEN

Aprea Expands Development of WEE1 Inhibitor After Seeing Early Clinical Activity Signs vs. Cancer

Aprea Therapeutics is accelerating enrollment in its ongoing Phase I trial of its targeted cancer therapy APR-1051, one of the precision oncology drug developer's two...

August 25 Seeking Alpha

Aprea Therapeutics records second consecutive surge, jumping another 22%

Aprea Therapeutics (APRE) stock surges on earnings beat and APR-1051 Phase 1 cancer trial updates—see key levels, cash runway and what's next.

August 12 Finanzen.ch

Aprea Therapeutics: Balance sheet for the expired quarter

Aprea Therapeutics published the balance sheet for the most recent quarter on 08/12/2026, which ended on 06/30/2026. A loss per...

Never miss news about Aprea Therapeutics

Track Aprea Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Aprea Therapeutics competitors & trending companies

Browse news for competitors to Aprea Therapeutics and other trending companies.